TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33028667

Group type: EXPERIMENTAL
Intervention: 12-miRNA biomarker panel
Number of subjects: 5248

Group type: COMPARATOR
Intervention: HP serology
Number of subjects: 5248

Group type: COMPARATOR
Intervention: PG 1/2 ratio
Number of subjects: 5248

Group type: COMPARATOR
Intervention: PG index
Number of subjects: 5248

Group type: COMPARATOR
Intervention: ABC method
Number of subjects: 5248

Group type: COMPARATOR
Intervention: CEA
Number of subjects: 5248

Group type: COMPARATOR
Intervention: CA19-9
Number of subjects: 5248
Study: 33029116

Group type: EXPERIMENTAL
Intervention: Val group
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Met group
Number of subjects: 58
Study: 33029135

Group type: EXPERIMENTAL
Intervention: 30 ml articaine 2%
Number of subjects: 117

Group type: COMPARATOR
Intervention: 30 ml bupivacaine 0.5%
Number of subjects: 117
Study: 33029262

Group type: EXPERIMENTAL
Intervention: Proposed VTE risk stratification protocol with patient education programs (Group A)
Number of subjects: 242

Group type: COMPARATOR
Intervention: 2005 Caprini risk assessment tool without education programs (Group B)
Number of subjects: 242
Study: 33029387

Group type: EXPERIMENTAL
Intervention: Secondary PPV with ILM plug
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33029427

Group type: EXPERIMENTAL
Intervention: Double pigtail ureteric stent
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Double pigtail ureteric stent with extraction string
Number of subjects: 105

Group type: COMPARATOR
Intervention: No ureteric stent
Number of subjects: 105
Study: 33029552

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed 100% whey protein formula (FA)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Standard, full-lactose, intact whey/casein infant formulas (FB)
Number of subjects: 256
Study: 33029615

Group type: EXPERIMENTAL
Intervention: Major and minor criteria for High Bleeding Risk (HBR) as defined by the Academic Research Consortium (ARC)
Number of subjects: 16580

Group type: EXPERIMENTAL
Intervention: Major criteria for HBR
Number of subjects: 16580

Group type: EXPERIMENTAL
Intervention: Minor criteria for HBR
Number of subjects: 16580
Study: 33029623

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33029732

Group type: EXPERIMENTAL
Intervention: PAD group
Number of subjects: 636

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: PAD type 1
Number of subjects: 636
Study: 33029743

Group type: EXPERIMENTAL
Intervention: ECMO treatment
Number of subjects: 29
Study: 33029899

Group type: EXPERIMENTAL
Intervention: Measurement of ingested and excreted calories using bomb calorimetry over 3 days.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight of stool samples during dietary intervention.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stool calories per gram for pellets.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stool measurement of kilocalories per gram.
Number of subjects: 0
Study: 33030436

Group type: EXPERIMENTAL
Intervention: Cognitively healthy older experimental participants
Number of subjects: 13

Group type: COMPARATOR
Intervention: Cognitively healthy older control participants
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Participants with dementia
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Questionnaire outcomes for usability and immersion
Number of subjects: 13
Study: 33030610

Group type: EXPERIMENTAL
Intervention: Agility t-test
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: 505 agility test
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Single-leg hop for distance test
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Side-hop test
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Countermovement jump test
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: 10-m sprint test
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: 20-m sprint test
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Tuck jump assessment (TJA)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Drop vertical jump (DVJ)
Number of subjects: 115
Study: 33030704

Group type: EXPERIMENTAL
Intervention: Teicoplanin (weight-based dosing regimen)
Number of subjects: 0
Study: 33030848

Group type: EXPERIMENTAL
Intervention: PD-L1 IC+ (ventana SP142 assay)
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: PD-L1 IC+ prevalence by anatomic location
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: PD-L1 IC status agreement
Number of subjects: 670
Study: 33030871

Group type: EXPERIMENTAL
Intervention: Surgical failure defined as apical descent greater than one third of the total vaginal length, anterior or posterior vaginal wall past the hymen, subsequent surgery or bothersome vaginal bulge.
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Worsening Pelvic Organ Prolapse Distress Inventory score.
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Worsening Urinary Distress Inventory score.
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Worsening Colorectal-Anal Distress Inventory score.
Number of subjects: 659
Study: 33030975

Group type: EXPERIMENTAL
Intervention: HE4 measurement
Number of subjects: 143
Study: 33031046

Group type: EXPERIMENTAL
Intervention: Virtual Reality Behavioral Activation, 50-minute weekly sessions for 4 weeks using a VR headset
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Self-report rating scales for acceptability, tolerability, and depression symptoms
Number of subjects: 1
Study: 33031354

Group type: EXPERIMENTAL
Intervention: Family-Assisted Severe Febrile Illness Therapy
Number of subjects: 107
Study: 33031412

Group type: EXPERIMENTAL
Intervention: Posterior spinal fusion (PSF) in AIS subjects
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both AIS and control subjects
Number of subjects: 30
Study: 33031542

Group type: EXPERIMENTAL
Intervention: Combination therapy of venetoclax plus ibrutinib for ≥12 months
Number of subjects: 0
Study: 33031789

Group type: EXPERIMENTAL
Intervention: 3-month DAPT
Number of subjects: 3652

Group type: EXPERIMENTAL
Intervention: 1-month DAPT
Number of subjects: 3652

Group type: COMPARATOR
Intervention: Historical control from XIENCE V USA study
Number of subjects: 3652
Study: 33031809

Group type: EXPERIMENTAL
Intervention: Cross-Linking treatment for fungal keratitis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33031861

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) ketamine infusions
Number of subjects: 134
Study: 33031955

Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg (up to 800 mg) as one intravenous administration, with a second optional administration after 12 hours.
Number of subjects: 330
Study: 33031971

Group type: EXPERIMENTAL
Intervention: Primary progressive aphasia variants (nonfluent, logopenic, semantic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Logopenic and semantic variants
Number of subjects: 0
Study: 33031977

Group type: EXPERIMENTAL
Intervention: ALS patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: ALS patients (excluding those with frontotemporal dementia)
Number of subjects: 22
Study: 33032328

Group type: EXPERIMENTAL
Intervention: Prenatal vitamins/multivitamins
Number of subjects: 2164

Group type: EXPERIMENTAL
Intervention: Medications
Number of subjects: 2164

Group type: EXPERIMENTAL
Intervention: Overall supplement intake
Number of subjects: 2164

Group type: EXPERIMENTAL
Intervention: Overall medication use
Number of subjects: 2164
Study: 33032489

Group type: EXPERIMENTAL
Intervention: Standard medical management with follow-up imaging
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Flow status (time-varying)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Mean blood pressure assessment
Number of subjects: 72
Study: 33032536

Group type: EXPERIMENTAL
Intervention: PG-GAN generated synthetic MRI images
Number of subjects: 303

Group type: COMPARATOR
Intervention: U-Net trained on patient data
Number of subjects: 303
Study: 33032541

Group type: EXPERIMENTAL
Intervention: Remote monitoring technology (Smart Angel™ app and Bluetooth monitors)
Number of subjects: 29
Study: 33032571

Group type: EXPERIMENTAL
Intervention: Screening for depressive symptoms using the Patient Health Questionnaire-9 (PHQ-9)
Number of subjects: 1203

Group type: EXPERIMENTAL
Intervention: Comorbidities associated with depressive symptoms
Number of subjects: 1203

Group type: EXPERIMENTAL
Intervention: Cardiovascular medication of ticagrelor
Number of subjects: 1203
Study: 33032615

Group type: EXPERIMENTAL
Intervention: Finger gaiting during tactile manipulation of a cuboid using a digital data glove with 29 sensors.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Finger gaiting as a mechanism underlying the manipulation task.
Number of subjects: 22
Study: 33032662

Group type: EXPERIMENTAL
Intervention: Aβ+NfL+
Number of subjects: 452

Group type: COMPARATOR
Intervention: Control group (multidomain interventions, omega-3 supplementation, multidomain plus omega-3 supplementation)
Number of subjects: 452
Study: 33032708

Group type: EXPERIMENTAL
Intervention: Lactate after 8 hours (L2)
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Lactate clearance (LC)
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Baseline lactate (L1)
Number of subjects: 671
Study: 33032892

Group type: EXPERIMENTAL
Intervention: Remote Ischaemic Conditioning (RIC)
Number of subjects: 50
Study: 33033006

Group type: EXPERIMENTAL
Intervention: MRI mapping of tumour deposits (TDs)
Number of subjects: 100
Study: 33033101

Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vedolizumab 150 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vedolizumab 75 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vedolizumab (all doses)
Number of subjects: 12
Study: 33033102

Group type: EXPERIMENTAL
Intervention: Fast algorithms as per 2015 European Society of Cardiology guidelines
Number of subjects: 2525
Study: 33033149

Group type: EXPERIMENTAL
Intervention: Obese patients (BMI ≥30 kg·m²)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Normal-weight patients (BMI <25 kg·m²)
Number of subjects: 203
Study: 33033150

Group type: EXPERIMENTAL
Intervention: Transthoracic two-dimensional shear-wave ultrasound elastography
Number of subjects: 354
Study: 33033800

Group type: EXPERIMENTAL
Intervention: 20 mg tadalafil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 33033885

Group type: EXPERIMENTAL
Intervention: Bremelanotide
Number of subjects: 1144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1144
Study: 33034006

Group type: EXPERIMENTAL
Intervention: Tofacitinib modified-release (MR) 11 mg once-daily (QD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tofacitinib immediate-release (IR) 5 mg twice-daily (BID)
Number of subjects: 0
Study: 33034050

Group type: EXPERIMENTAL
Intervention: Low CRYM expression levels in PCa patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRYM
Number of subjects: 0
Study: 33034194

Group type: EXPERIMENTAL
Intervention: CC-90011
Number of subjects: 0
Study: 33034295

Group type: EXPERIMENTAL
Intervention: Intravital microscopy (IVM) during surgical resection
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravital microscopy (IVM) during administration of vasopressors or fluid boluses
Number of subjects: 20
Study: 33034567

Group type: EXPERIMENTAL
Intervention: emma app (Ecological Momentary Assessment and Intervention)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: emma app (Safety Plan Modules)
Number of subjects: 14
Study: 33034806

Group type: EXPERIMENTAL
Intervention: Triple antithrombotic therapy (TAT)
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Dual antithrombotic therapy (DAT)
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Non-vitamin K antagonist oral anticoagulants (NOACs)
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Factors predictive of TAT adoption
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Factors predictive of DAT adoption
Number of subjects: 654
Study: 33034839

Group type: EXPERIMENTAL
Intervention: Ribociclib (350 mg/m2) administered following radiotherapy in 28-day cycles
Number of subjects: 10
Study: 33034900

Group type: EXPERIMENTAL
Intervention: Cooling treatment (ice pack or cold gel pad)
Number of subjects: 1233

Group type: EXPERIMENTAL
Intervention: Cooling treatment (cold gel pad) + compression
Number of subjects: 1233

Group type: COMPARATOR
Intervention: Cooling treatment (ice pack)
Number of subjects: 1233
Study: 33035067

Group type: EXPERIMENTAL
Intervention: Online Parent Training for Irritability and Disruptive Behavior
Number of subjects: 0
Study: 33035138

Group type: EXPERIMENTAL
Intervention: Indwelling catheter
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: Clean intermittent catheterization
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Voiding spontaneously
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: SF-12 physical scores
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: Diminished hand function
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: Unemployment
Number of subjects: 1260
Study: 33035333

Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel), an anti-CD19 CAR T-cell therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapid CAR T-cell expansion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Number of CD8 and CCR7+CD45RA+ T cells infused
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Host systemic inflammation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical covariates (ECOG performance status, age, disease subtype, disease stage, IPI score)
Number of subjects: 0
Study: 33036555

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention consisting of 10-min exposure via a headset with sceneries, background meditation music, and breathing exercises.
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention
Number of subjects: 108
Study: 33036564

Group type: EXPERIMENTAL
Intervention: Luminex xTAG® multiplex PCR testing for enteric pathogens
Number of subjects: 269
Study: 33037018

Group type: EXPERIMENTAL
Intervention: UroCAD (Urine Exfoliated Cells Copy Number Aberration Detector)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Cytology tests
Number of subjects: 190
Study: 33037105

Group type: EXPERIMENTAL
Intervention: 250 mg/day gefitinib (oral) and 2.0 mg/m² topotecan
Number of subjects: 19
Study: 33037117

Group type: EXPERIMENTAL
Intervention: IT MEDI9197 0.005-0.055 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: IT MEDI9197 0.012 mg plus durvalumab 1500 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: IT MEDI9197
Number of subjects: 52
Study: 33037135

Group type: EXPERIMENTAL
Intervention: BI 905711, a novel tetravalent bispecific antibody targeting TRAILR2 and CDH17
Number of subjects: 0
Study: 33037746

Group type: EXPERIMENTAL
Intervention: Culturally competent transplant care intervention (HKTP)
Number of subjects: 44
Study: 33037874

Group type: EXPERIMENTAL
Intervention: IntelliCare for College Students app
Number of subjects: 20
Study: 33038155

Group type: EXPERIMENTAL
Intervention: Red light at 675 nm
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Far red light at 750 nm
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Far red light at 800 nm
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard cobalt blue light
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Light source at 750 and 800 nm
Number of subjects: 30
Study: 33038188

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention (MBI)
Number of subjects: 96
Study: 33038190

Group type: EXPERIMENTAL
Intervention: Denosumab (120 mg subcutaneously) once every 4 weeks during the treatment phase, with loading doses on days 8 and 15 of the first cycle.
Number of subjects: 132
Study: 33038223

Group type: EXPERIMENTAL
Intervention: HARPOON beating heart mitral valve repair system
Number of subjects: 65
Study: 33038231

Group type: EXPERIMENTAL
Intervention: Recurrent syncope
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Cardiac syncope
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Syncope with unknown aetiology
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: >3 previous episodes of syncope
Number of subjects: 1790
Study: 33038277

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy with nab-paclitaxel and gemcitabine
Number of subjects: 600
Study: 33038286

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg daily
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Edoxaban 30 mg daily
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg daily (patients meeting criteria for dose reduction)
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Edoxaban 30 mg daily (patients meeting criteria for dose reduction)
Number of subjects: 562
Study: 33038344

Group type: EXPERIMENTAL
Intervention: Fish oil lipid emulsion (FOLE) 1 g/kg/d
Number of subjects: 262

Group type: COMPARATOR
Intervention: Soybean oil intravenous lipid emulsion (SOLE) ≤3 g/kg/d
Number of subjects: 262
Study: 33038346

Group type: EXPERIMENTAL
Intervention: Candidate anxiolytics tested in human models of anxiety using anxiety-potentiated startle.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anxiety-potentiated startle model.
Number of subjects: 0
Study: 33038902

Group type: EXPERIMENTAL
Intervention: Anger attacks (≥9 in the past month)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Anger attacks at baseline
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Participants with anger attacks
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Participants with aggressive behaviors
Number of subjects: 293

Group type: COMPARATOR
Intervention: Participants without anger attacks
Number of subjects: 293
Study: 33038933

Group type: EXPERIMENTAL
Intervention: PROMIS-29
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Impact Stratification Score (ISS) based on PROMIS-29 items
Number of subjects: 1500

Group type: COMPARATOR
Intervention: MTurk data collection
Number of subjects: 1500
Study: 33039202

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Physical activity support planning
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Session on using support
Number of subjects: 73
Study: 33039403

Group type: EXPERIMENTAL
Intervention: Baveno VI criteria combined with spleen stiffness measurement (cut-off 46 kPa)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Baveno VI criteria
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Spleen stiffness measurement (cut-off ≤46.0 kPa)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Combined model (Baveno VI criteria and spleen stiffness measurement cut-off ≤46 kPa)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Expanded Baveno VI criteria
Number of subjects: 341
Study: 33039474

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33039599

Group type: EXPERIMENTAL
Intervention: Brigatinib 90 mg daily for 7 days, then escalated to 180 mg daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 20
Study: 33039812

Group type: EXPERIMENTAL
Intervention: Intraperitoneal oxaliplatin delivered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) at a dose of 90 mg/m
Number of subjects: 10
Study: 33039989

Group type: EXPERIMENTAL
Intervention: New MDR-TB regimens containing bedaquiline, pretomanid, and linezolid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care for MDR-TB patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New MDR-TB regimens
Number of subjects: 0
Study: 33040013

Group type: EXPERIMENTAL
Intervention: VitalScan MCG (Creavo Medical Technologies, UK)
Number of subjects: 270
Study: 33040020

Group type: EXPERIMENTAL
Intervention: Severe hARF (PaO2/FiO2 <100 mm Hg)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Moderate hARF (PaO2/FiO2 101-200 mm Hg)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Mild hARF (PaO2/FiO2 201-300 mm Hg)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Age ≥65 years
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: PaO2/FiO2 ratio ≤200 mm Hg
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Respiratory failure at admission
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Moderate-to-severe impairment in PaO2/FiO2
Number of subjects: 412
Study: 33040383

Group type: EXPERIMENTAL
Intervention: Omnipod Insulin Management System
Number of subjects: 286

Group type: COMPARATOR
Intervention: Multiple daily injection therapy
Number of subjects: 286
Study: 33040420

Group type: EXPERIMENTAL
Intervention: UCSF downstaging (UCSF-DS)
Number of subjects: 2002

Group type: EXPERIMENTAL
Intervention: All-comers policy
Number of subjects: 2002

Group type: EXPERIMENTAL
Intervention: AFP score ≤2 points
Number of subjects: 2002

Group type: EXPERIMENTAL
Intervention: Double Eligibility Criteria (DEC)
Number of subjects: 2002
Study: 33040580

Group type: EXPERIMENTAL
Intervention: Quantitative flow ratio (QFR) based functional SYNTAX score (FSS)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 607
Study: 33040720

Group type: EXPERIMENTAL
Intervention: Trastuzumab treatment
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: cAMP Pathway Protein Retention
Number of subjects: 23
Study: 33041107

Group type: COMPARATOR
Intervention: Usual care arm of Urban Training (NCT01897298)
Number of subjects: 291

Group type: COMPARATOR
Intervention: PROactive initial validation (NCT01388218)
Number of subjects: 291
Study: 33041337

Group type: EXPERIMENTAL
Intervention: Overall alcohol consumption (drinks/week)
Number of subjects: 226162

Group type: EXPERIMENTAL
Intervention: Drinking pattern (1-3 days/week vs 4-7 days)
Number of subjects: 226162
Study: 33041987

Group type: EXPERIMENTAL
Intervention: Semantic Organization Strategy Training (SOST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychoeducation Intervention (PI)
Number of subjects: 0
Study: 33042202

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) and aromatase inhibitor therapy (AIT)
Number of subjects: 142
Study: 33042366

Group type: EXPERIMENTAL
Intervention: Integrative dance classes (12-week duration)
Number of subjects: 7
Study: 33042568

Group type: EXPERIMENTAL
Intervention: SINEX program (12-week exercise program with physiotherapist-supervised sessions)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: SINEX program
Number of subjects: 7